Editorial: Don’t rush to rehabilitate Hwang
By Editorial,
Nature
| 01. 21. 2014
An article published on Nature’s website last week has created quite a buzz in South Korea. It details efforts by former Seoul National University cloning specialist Woo Suk Hwang to rehabilitate his scientific career after he was found in 2006 to have been involved in fraud. Some in South Korea are taking the article as a sign that Hwang is now producing great science and is once again lauded by the scientific community. Stock prices of companies with connections to Hwang’s work have apparently jumped. It is as if many of the people talking and writing about the article have not read it. They and others can do so now if they wish: it appears as a News Feature on page 468.
As readers will see, the article is not a show of support for Hwang’s research. Nor is it an attack. It is the story of a rare event: a scientist attempting with some success to dig himself out from the depths of ignominy. It is a journalistic exercise, not a scientific endorsement. And it was commissioned to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...